Contribution of Cyclin-dependent Kinase Inhibitor 1B Genotypes to Childhood Leukemia Risk

In Vivo. 2022 Jul-Aug;36(4):1637-1642. doi: 10.21873/invivo.12874.

Abstract

Background/aim: Although genetic differences in cell-cycle control genes have been associated with cancer risk, to our knowledge, no report has specifically examined the role of gene variants in childhood acute lymphoblastic leukemia (ALL). Cyclin-dependent kinase inhibitor 1B (CDKN1B; also known as p27/KIP1) is a cell-cycle regulating gene. This study aimed at investigating the association between CDKN1B genotypes and childhood ALL risk.

Materials and methods: In 266 childhood ALL cases and 266 healthy controls, the CDKN1B rs34330 and 2066827 polymorphisms were genotyped, and the association of CDKN1B genotypes with childhood ALL risk were analyzed.

Results: The genotypes of CDKN1B rs34330 and 2066827 were similarly distributed between the control and case groups (p for trend=0.8718 and 0.4030, respectively). The allelic frequency also exhibited no statistical difference (p=1.0000 and 0.6666, respectively). There was no significant interaction between CDKN1B genotypes and age or sex.

Conclusion: CDKN1B genotypes were not found to be minor contributors to childhood ALL susceptibility in Taiwan.

Keywords: CDKN1B; Taiwan; childhood leukemia; genotype; polymorphism.

MeSH terms

  • Child
  • Cyclin-Dependent Kinase Inhibitor p27* / genetics
  • Gene Frequency
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Polymorphism, Single Nucleotide
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / genetics
  • Taiwan

Substances

  • CDKN1B protein, human
  • Cyclin-Dependent Kinase Inhibitor p27